HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Related Collections Related Article

Ann Thorac Surg 1996;61:1476
© 1996 The Society of Thoracic Surgeons

---

Discussion

Discussion

The first 20% of the full text of this article appears below.

See also page 1470.

DR DANIEL L. MILLER (Louisville, KY): That was an excellent presentation. The data presented will be very important for years to come.

The question I have is in regard to the 58 patients who had greater than three markers present. I would like to know, was there any correlation between the number of markers present in these patients and the mode of cancer death such as local recurrent disease versus distant recurrent disease, and if so, are there any future plans to institute specific adjuvant therapy in regard to the markers and number of markers found?

DR HARPOLE: Thank you, Dr Miller. The minimal follow-up period on each patient was more than 5 years. For patients who had cancer recurrence, 85% of the recurrences were located at . . . [Full Text of this Article]

Related Article

Angiogenesis and Molecular Biologic Substaging in Patients With Stage I Non-Small Cell Lung Cancer

David H. Harpole, Jr, William G. Richards, James E. Herndon, II, and David J. Sugarbaker
Ann. Thorac. Surg. 1996 61: 1470-1476. [Abstract] [Full Text]